1. Home
  2. KVHI vs ALXO Comparison

KVHI vs ALXO Comparison

Compare KVHI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KVH Industries Inc.

KVHI

KVH Industries Inc.

HOLD

Current Price

$11.55

Market Cap

208.4M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.99

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KVHI
ALXO
Founded
1978
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Radio And Television Broadcasting And Communications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.4M
240.8M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
KVHI
ALXO
Price
$11.55
$1.99
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
146.1K
698.5K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
33.33
26.36
EPS
0.03
N/A
Revenue
$9,622,000.00
N/A
Revenue This Year
$28.90
N/A
Revenue Next Year
$31.85
N/A
P/E Ratio
$358.00
N/A
Revenue Growth
3.82
N/A
52 Week Low
$5.09
$0.41
52 Week High
$11.45
$2.66

Technical Indicators

Market Signals
Indicator
KVHI
ALXO
Relative Strength Index (RSI) 66.97 54.37
Support Level $5.56 $1.44
Resistance Level N/A $2.27
Average True Range (ATR) 0.79 0.14
MACD 0.03 0.01
Stochastic Oscillator 96.97 52.94

Price Performance

Historical Comparison
KVHI
ALXO

About KVHI KVH Industries Inc.

KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: